Literature DB >> 16127083

Postantibiotic effect of DX-619 against 16 gram-positive organisms.

G A Pankuch1, P C Appelbaum.   

Abstract

The in vitro postantibiotic effects (PAEs), the postantibiotic sub-MIC effects (PA-SMEs), and the sub-MIC effects (SMEs) of DX-619 were determined for 16 gram-positive organisms. DX-619 pneumococcal, staphylococcal, and enterococcal PAE ranges were 1.7 to 5.0 h, 0.7 to 1.8 h, and 1.2 to 6.5 h, respectively. The PA-SME ranges (0.4x MIC) for pneumococci, staphylococci, and enterococci were 5.2 to >8.6 h, 2.1 to 8.3 h, and 4.9 to >10.0 h, respectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127083      PMCID: PMC1195407          DOI: 10.1128/AAC.49.9.3963-3965.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

Review 1.  The post-antibiotic effect.

Authors:  F M MacKenzie; I M Gould
Journal:  J Antimicrob Chemother       Date:  1993-10       Impact factor: 5.790

Review 2.  The post-antibiotic sub-MIC effect in vitro and in vivo.

Authors:  O Cars; I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

3.  Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

4.  Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

Authors:  I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

Review 5.  Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens.

Authors:  W Craig
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

6.  Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

  6 in total
  3 in total

1.  In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.

Authors:  Michael J Pucci; Jijun Cheng; Steven D Podos; Christy L Thoma; Jane A Thanassi; Douglas D Buechter; Gohar Mushtaq; Gerald A Vigliotti; Barton J Bradbury; Milind Deshpande
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

2.  In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

Authors:  Michael D Huband; Patricia A Bradford; Linda G Otterson; Gregory S Basarab; Amy C Kutschke; Robert A Giacobbe; Sara A Patey; Richard A Alm; Michele R Johnstone; Marie E Potter; Paul F Miller; John P Mueller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

3.  In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.

Authors:  Michael J Pucci; Steven D Podos; Jane A Thanassi; Melissa J Leggio; Barton J Bradbury; Milind Deshpande
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.